Psychedelics and mental health are increasingly discussed together, but the subject still needs far more precision than hype. In this article, I outline how I think about psychedelics as a clinical psychologist and researcher: with curiosity, restraint, and attention to both therapeutic potential and real limitations.
Psychedelics are one of those subjects that attract both serious inquiry and a great deal of projection. With mental health difficulties becoming more widespread, and many existing treatments proving limited, exhausting, or difficult to sustain, the renewed interest in psychedelics is not hard to understand. The interest is not only cultural, it is also clinical; psychedelics may offer a different therapeutic pathway, and that possibility is important enough to deserve serious, careful attention.
Why Psychedelics Matter Clinically
Psychedelic research matters especially now because the field is no longer defined by speculation or stigma alone. There is already a substantial body of research, from observational and qualitative work to systematic reviews and numerous clinical trials worldwide, unequivocally pointing to real therapeutic potential in mental health. At the end of this post, I’ve included a short reading list of strong recent studies and reviews (2024–2026) for readers who want to go deeper. If you’re curious and would like more tailored recommendations, you’re very welcome to message me.
At the same time, serious work in this field still has to deal with safety, study design, expectancy effects, reporting quality, decolonization, accessibility, and the fact that many study samples still do not adequately reflect the broader populations who may eventually seek or need these treatments.
I take psychedelics seriously because they may widen the range of treatment options in mental health, beyond long-term medication with variable benefit and significant side-effect burden. The evidence is stronger in some areas than in others, but the possibility is real enough to deserve careful attention.
What Is Being Studied, and What Is Being Sold
There is already a well-developed research base on psychedelics, alongside a great deal of hype, misuse, and conceptual confusion. What matters to me is not adding to the noise, but helping draw clearer distinctions: between recreational use and therapeutic use, between enthusiasm and evidence, and between what is being explored responsibly and what is merely being sold.
These distinctions matter because the strongest part of this field is not the rhetoric around it, but the research itself. For example, psilocybin trials in depression have shown promising antidepressant effects, though the picture is not uniformly straightforward. Some findings are stronger than others, especially under stricter conditions. That is what serious evidence often looks like: not miracle, not collapse, but a theory being tested carefully.
What Emerges in Psilocybin Experience
Because my own research focused on psilocybin, I am especially attentive to the psychological richness of the experience itself. In my dissertation research in Portuguese population, the data did not point to one particular effect that takes over. It clustered around several recurring domains: emotional and psychological experiences, physical sensations, themes of connection and unity, cognitive and perceptual changes, and personal transformation. The theme of personal transformation was the most commonly reported experience, but it was not the whole picture. That matters clinically.
A meaningful experience is not automatically a therapeutic one.
A destabilizing experience is not automatically harmful.
Intensity is not the same as improvement.
These distinctions are part of what makes the field interesting, and part of what makes it easy to oversimplify.
Why hype and fear both distort the field
I am not interested in talking about psychedelics as a miracle or as a menace. Both are distortions.
The field becomes less credible and ultimately less useful the moment it is taken over by hype, fear, or greed. More broadly, questions of access, affordability, therapist training, cultural context, and who actually gets included in trials are not side issues. If psychedelic treatments expand, those questions will shape whether the field becomes genuinely useful or simply another domain of prestige care for a narrow population.
What follows
Curiosity is not enough here. Good intentions are not enough either. If this field is to mature, it needs safeguards, protocols, ethical clarity, and regulation strong enough to protect vulnerable people from confusion, misuse, and exploitation. That is not an argument against psychedelics. It is part of taking their potential seriously.
That is the perspective I want to bring to my subsequent posts on this subject: careful, evidence-aware, and psychologically grounded. This series will build step by step: first by clarifying what different psychedelics are, how they work, and what they do or do not share; then by looking more closely at how they affect the mind, what kinds of experiences they can produce, and why those differences matter.
References:
Dominiak, M., Gędek, A., Modrzejewski, S., Permoda-Pachuta, A., & Antosik, A. Z. (2025).
Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. Journal of Clinical Medicine, 15(1), 253.
DOI: 10.3390/jcm15010253
Soliman, P. S., Curley, K., Nishikawa, T., & Haass-Koffler, C. L. (2024).
In the New Era of Psychedelic Assisted Therapy: A Systematic Review of Study Methodology in Randomized Controlled Trials. Psychopharmacology.
DOI: 10.1007/s00213-024-06598-6
Raison, C. L., Demetrashvili, M. F., Capra, W., Harmer, B., Page, S., Hellerstein, D. J., Gukasyan, N., et al. (2023).
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853.
DOI: 10.1001/jama.2023.14530
Mertens, L. J., Koslowski, M., Wolff, M., Betzler, F., Brand, M., Evens, R., et al. (2026).
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression. JAMA Psychiatry.
DOI: https://doi.org/10.1001/jamapsychiatry.2026.0132
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., et al. (2021).
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033.
DOI: 10.1038/s41591-021-01336-3
Mitchell, J. M., Ot’alora G, M., van der Kolk, B., et al. (2023).
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473–2480.
DOI: 10.1038/s41591-023-02565-4
Seybert, C., Schimmers, N., Silva, L., Breeksema, J. J., Veraart, J., Bessa, B. S., d’Orsi, D., Schoevers, R. A., & Oliveira-Maia, A. J. (2025).
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review. The Lancet Psychiatry, 12(1), 54–66.
DOI: 10.1016/S2215-0366(24)00333-X
